BG
ECYT

Bellevue Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Bellevue Group’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-100,000
Closed -$310K – 136
2016
Q1 		$310K Buy
+100,000
New +$326K 0.06% 117

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bellevue Group's ECYT Position: Q2 2016 in Review

Bellevue Group sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2016, closing a stake of 100,000 shares — an estimated $310K sold.

Bellevue Group first reported a position in ECYT in Q1 2016 and held it in 1 quarter. The position peaked at $310K in Q1 2016. 96 funds tracked by Wall St. Rank hold ECYT as of Q2 2016.

  • Bellevue Group reported no remaining Endocyte, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
  • Bellevue Group sold 100,000 Endocyte, Inc. Common Stock shares in Q2 2016, an estimated $310K.
  • Bellevue Group first reported a position in Endocyte, Inc. Common Stock in Q1 2016 and held it in 1 quarter.
  • Bellevue Group's Endocyte, Inc. Common Stock position peaked at $310K in Q1 2016.
  • 96 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2016.

Based on Bellevue Group's 13F filing for Q2 2016, filed 12 Aug 2016.